News

The agency has granted the application priority review, setting a Prescription Drug User Fee Act (PDUFA) target action date of 9 November 2025. The therapy has secured several

This designation is intended for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). Mesutoclax becomes the inaugural BCL2 inhibitor to receive BTD recognition in

The funds are also used in the enhancement of the company’s RNA delivery technologies. A corporate venture capital firm spearheaded the financing round, with participation from new investor

The strategic decision follows thorough independent valuations of both entities, with the merger contingent upon approval from shareholders of both companies. Moore Financial Consulting conducted a third-party analysis

It is said to be the second grant awarded by the foundation to the company and marks the continuation of a productive five-year collaboration between the parties. Evotec’s

The fast-track application included top-line data from the double-blind randomised Phase II clinical trial, which showed efficacy on the modified Unified Multiple System Atrophy Rating Scale (UMSARS)I alongside

These patents have a base patent term extending until June 2040. This is contingent upon the alteration due to any delays in the prosecution process and extension to

Last month, PCI signed a deal to acquire Ajinomoto Althea, a subsidiary of Japan-based Ajinomoto. This acquisition is part of PCI’s investment strategy to enhance its manufacturing capabilities

This fixed-dose combo of Perjeta (pertuzumab) and Herceptin (trastuzumab), delivered via SC injection along with intravenous chemotherapy, offers a subcutaneous (SC) treatment option for human epidermal growth factor